Elie Levy, MD
Dermatology · Burien, WANPI 1427053834
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,180 of the $3,286 with a category attached, or 66.3%. AbbVie accounts for 70.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $1,321 and has fallen 58.0% since, to $554 in 2025.
Across 114 payments — averaging $28.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$263
- Novartis$145
- Sanofi$119
- Organogenesis Inc.$102
- E.r. Squibb & Sons, L.L.C.$86
- plus $268 from 8 others
Across 21 payments — averaging $7759.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$132K
- Incyte Corporation$20K
- Amgen$11K
What the payments were for
- Speaking & faculty fees$1,08233%
- Food & beverage$2,18066%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $2,303 |
| Johnson & Johnson | 19 | $263 |
| Novartis | 7 | $145 |
| Sanofi | 5 | $119 |
| Organogenesis Inc. | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $86 |
| LEO Pharma Inc. | 4 | $79 |
| Biofrontera Inc. | 2 | $48 |
| Amgen | 2 | $45 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Organon | 1 | $13 |
How this compares
$3,286 in reported general payments places this provider in the 70th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 12 | $628 |
| Triamcinolone Acetonide | 41 | $574 |
| Ketoconazole | 32 | $395 |
| Doxycycline Hyclate | 16 | $382 |
| Mometasone Furoate | 16 | $331 |
| Mupirocin | 30 | $284 |
| Terbinafine Hcl | 12 | $208 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Burien
- Robert ChowBurien$6K
- Clive LiuBellevue$2.9M
- Vivian ShiSeattle$971K
- William WerschlerSpokane$948K
- Daniel LevyBonney Lake$541K
- Daniel SugaiBellevue$302K
- Ting-Lin YangBellingham$124K
- James CollyerSeattle$115K
- Cameron ChesnutSpokane$93K
- Alison YoungSeattle$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.